FinlandFinland

Researchers find that creation of induced pluripotent stem cells is linked to genetic abnormalities

03.03.2011

Helsinki/Toronto – Induced pluripotent stem cells from a patient’s own cells must be screened for genetic failures before any clinical use, new research from Finnish and Canadian researchers suggest. In Nature the researchers from Mount Sinai Hospital and Biomedicum Stem Cell Center at University of Helsinki under Timo Otonkoski report that the reprogramming process for generating iPS cells (i.e., cells that can then be 'coaxed' into becoming a variety of cell types for use in regenerative medicine) is associated with inherent DNA damage. Carrying out genome-wide comparative SNP analyses of human iPS cells with their respective parental cells, they identified genetic rearrangements and copy number variations in each of the assessed cell lines. "Our analysis shows that these genetic changes are a result of the reprogramming process itself, which raises the concern that the resultant cell lines are mutant or defective," said Dr. Nagy, a Senior Investigator at Mount Sinai Hospital. "These mutations could alter the properties of the stem cells, affecting their applications in studying degenerative conditions and screening for drugs to treat diseases.“ In the longer term, this discovery has important implications in the use of these cells for replacement therapies in regenerative medicine. "Our study highlights the need for rigorous characterization of generated iPS lines, especially since several groups are currently trying to enhance reprogramming efficiency," said Dr. Samer Hussein at Biomedicinium Stem Cell Center. "For example, increasing the efficiency of reprogramming may actually reduce the quality of the cells in the long run, if genomic integrity is not accurately assessed." Both teams found that iPS cells had more genetic abnormalities than their originating cells and embryonic stem cells. Interestingly, however, the simple process of growing the freshly generated iPS cells for a few weeks selected against the highly mutant cell lines, and thus most of the genetic abnormalities were eventually 'weeded out.'

FinlandFinland

08.03.2012

The vaccine research centre of the University of Tampere in Finland has out­licenced a candidate combined prophylactic vaccine against norovirus and rota­virus infections. The Japanese vaccine venture UMN Pharma Inc. acquired the...

FinlandFinland

07.03.2012

Finnish protein manufacturer Vectron Biosolutions AS has completed a study comparing different expression technologies. According to Vectron, their proprietary E. coli expression technology gave higher yields for seven out of ten...

FinlandFinland

02.03.2012

Lappeenranta – Finnish paper industry major UPM plans to invest in an industry-scale biorefinery producing biofuels from crude tall oil, a by-product of the wood pulp manufacturing process. UPM’s total investment will amount to...

FinlandFinland

18.12.2011

Helsinki/Göttingen – Finnish laboratory supplier Biohit Oyj has sold its liquid handling business for €68m to German process and labtech provider Sartorius AG. Osmo Suovaniemi, founder and Chairman of the Board at Biohit,...

FinlandFinland

17.12.2011

Porvoo/Chalfont St. Giles – GE Healthcare and Neste Jacobs have formed a strategic alliance to drive worldwide self-sufficiency in blood plasma fractionation. Finnish-based Neste Jacobs Oy, a global expert in plant engineering...

FinlandFinland

31.10.2011

Bresso/Turku – The wedding's off between Newron and Biotie. The bride has run away. Shares in Italy's Newron Pharmaceuticals plunged after its proposed merger with Biotie Therapies Corp was called off by the Finnish firm....

FinlandFinland

28.09.2011

Turku/ Bresso – It is both good and bad news for the Italian biotechnology sector: Finnish Biotie Therapies ASA has signed an agreement to acquire Newron Pharmaceuticals S.p.A. for €45 million. On the down side, Italy loses one...

FinlandFinland

04.04.2011

Hafnarfjodur – Actavis Group CEO Claudio Albrecht announced at the beginning of February that the company may go public within the next 2-3 years, although it isn’t clear whether the generics manufacturer would conduct an IPO,...

FinlandFinland

11.02.2011

Helsinki – Using laser light to destroy tumour cells lodged in lymphatic vessels can halt the spread of cancer, Finnish researchers headed by Tuomas Tammela have demonstrated. Their approach to destroy the tumour cells, which use...

Displaying results 1 to 10 out of 96

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-finland/article/researchers-find-that-creation-of-induced-pluripotent-stem-cells-is-linked-to-genetic-abnormalities.html

Image Gallery

Stock list

All quotes

TOP

  • THROMBOGENICS (B)22.00 EUR16.5%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CLAVIS PHARMA (N)2.18 NOK6.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • DIAGENIC (N)0.79 NOK-38.3%
  • PAION (D)3.08 EUR-18.5%

TOP

  • WILEX (D)1.04 EUR79.3%
  • CO.DON (D)3.10 EUR74.2%
  • BIOTECH PHARMACON (N)18.20 NOK56.9%

FLOP

  • CYTOS (CH)0.15 CHF-94.8%
  • BIONOR PHARMA (N)2.08 NOK-48.6%
  • DIAGENIC (N)0.79 NOK-45.9%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6041.2%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)10.75 GBP593.5%

FLOP

  • CYTOS (CH)0.15 CHF-96.5%
  • EVOCUTIS (UK)0.25 GBP-91.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main

7th DVFA Life Science Conference

White Paper